Avid Bioservices Inc (CDMO)

[Protector]

Additional Comments on PPHM quarterly based on transcript.

Shan:

With over 150 clinical centers across all 14 planned countries now opened for enrolment, our planned for site activation is almost complete and we remain on track to complete enrolment of approximately 600 patients by the end of calendar year 2015.

1) We can now for SURE remove Poland and Singapore of the list, the Italian protocol is simply wrong, as were 3 others, but the Italians seem not to care to correct it. I am sure this is NOT PPHM's doing, neither under their control.

2) France is open, the hospitals info was right the National Cancer Institute information "on wait" is wrong.

3) 151 is not the end point. As expected there will be some more centres opened. Probably completing Greece and Hungary and probably increase France and Italy.

Shan:

As a reminder, this Phase III registration filed is designed with two planned interim analyses both of which are event driven.

I like it that he puts in this reminder. It kind of emphasizes that these interims are not just an anti-tempering measure but have other importance.

Shan:

And this is exactly the type of data which we can build upon to guide further bavituximab [ph] development program and at the same time expand our growing network of world class experts and thought leaders in that field of cancer immunology.

Thought leaders is what he uses for KOL's. The "growing" fits previous quarterly statement of CEO King about the few dozen of collaborations and the biopharms group statistics on the PPHM Bavituximab, Avid and Brekken followers that seem to take a serious acceleration. Many may not agree with me but I find this Shan statement the most valuable of the complete quarterly.

Q&A King:

But secondly its actively working with some of the key opinion leaders in this area and we are collaborating several of these programs we’ve talked about with well known, well respected individuals on the I-O space and that’s the other key as to get them to have the positive experience in their hands. And again that’s all under-way, so yeah, I think we’ve make great progress and we going to keep that until it’s a household name in the I-O space.

Those suggesting that the KOL are just on a payroll to leverage the group picture can think again. And so can those that thought SK was joking when he first use the term "household name". Apparently he was not because here it is again.

Q&A King:

All of this preclinical and translational work is important in order to chart the next clinical course as well as serving at the further validation of the immuno regulatory [ph] mechanism of action that the founder of our technology late Dr. Phil Thorpe was such a champion of. We feel strongly in our mission and believe in its value and that that value will be reflected in our share price as company milestones are reached.

I agree, milestone-grade events, not your average conference or dog & pony show PR.

There is much more in there but the above are IMO the points I like the most.